OBJECTIVES: This study aimed to quantify nonenhancing tumor (NT) component in clear cell renal cell carcinoma (ccRCC) and assess its association with histologically defined tumor necrosis, stage, and survival outcomes. METHODS: Among 183 patients with ccRCC, multi-institutional changes in computed tomography attenuation of tumor voxels were used to quantify percent of NT. Associations of NT with histologic tumor necrosis and tumor stage/grade were tested using Wilcoxon signed rank test and with survival outcomes using Kaplan-Meier curves/Cox regression analysis. RESULTS: Nonenhancing tumor was higher in ccRCC with tumor necrosis (11% vs 7%; P = 0.040) and higher pathological stage (P = 0.042 and P < 0.001, respectively). Patients with greater NT had higher incidence of cancer recurrence after resection (P < 0.001) and cancer-specific mortality (P < 0.001). CONCLUSION: Nonenhancing tumor on preoperative computed tomographic scans in patients with ccRCC correlates with tumor necrosis and stage and may serve as an independent imaging prognostic biomarker for cancer recurrence and cancer-specific survival.
OBJECTIVES: This study aimed to quantify nonenhancing tumor (NT) component in clear cell renal cell carcinoma (ccRCC) and assess its association with histologically defined tumor necrosis, stage, and survival outcomes. METHODS: Among 183 patients with ccRCC, multi-institutional changes in computed tomography attenuation of tumor voxels were used to quantify percent of NT. Associations of NT with histologic tumor necrosis and tumor stage/grade were tested using Wilcoxon signed rank test and with survival outcomes using Kaplan-Meier curves/Cox regression analysis. RESULTS: Nonenhancing tumor was higher in ccRCC with tumor necrosis (11% vs 7%; P = 0.040) and higher pathological stage (P = 0.042 and P < 0.001, respectively). Patients with greater NT had higher incidence of cancer recurrence after resection (P < 0.001) and cancer-specific mortality (P < 0.001). CONCLUSION: Nonenhancing tumor on preoperative computed tomographic scans in patients with ccRCC correlates with tumor necrosis and stage and may serve as an independent imaging prognostic biomarker for cancer recurrence and cancer-specific survival.
Authors: Martin Pichler; Georg C Hutterer; Thomas F Chromecki; Johanna Jesche; Karin Kampel-Kettner; Peter Rehak; Karl Pummer; Richard Zigeuner Journal: Am J Clin Pathol Date: 2012-02 Impact factor: 2.493
Authors: Jeong Kon Kim; Tae Kyoung Kim; Han Jong Ahn; Chung Soo Kim; Kyu-Rae Kim; Kyoung-Sik Cho Journal: AJR Am J Roentgenol Date: 2002-06 Impact factor: 3.959
Authors: Shomik Sengupta; Christine M Lohse; Bradley C Leibovich; Igor Frank; R Houston Thompson; W Scott Webster; Horst Zincke; Michael L Blute; John C Cheville; Eugene D Kwon Journal: Cancer Date: 2005-08-01 Impact factor: 6.860
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Ivan Pedrosa; Maryellen R Sun; Matthew Spencer; Elizabeth M Genega; Aria F Olumi; William C Dewolf; Neil M Rofsky Journal: Radiographics Date: 2008 Jul-Aug Impact factor: 5.333
Authors: Richard Zigeuner; Georg Hutterer; Thomas Chromecki; Arvin Imamovic; Karin Kampel-Kettner; Peter Rehak; Cord Langner; Karl Pummer Journal: Eur Urol Date: 2008-11-28 Impact factor: 20.096
Authors: Lin Lu; Firas S Ahmed; Oguz Akin; Lyndon Luk; Xiaotao Guo; Hao Yang; Jin Yoon; A Aari Hakimi; Lawrence H Schwartz; Binsheng Zhao Journal: Front Oncol Date: 2021-05-27 Impact factor: 6.244